文摘
Use of Act-D over MTX had an incremental cost effectiveness ratio (ICER) of $56,215. With sensitivity analysis any toxicity associated with Act-D inflated the ICER. If goal is avoidance of multi-agent chemotherapy, any MTX regimen outperformed Act-D.